Authors Philippe Lucas, MA PhD, Susan Boyd, PhD, M -J Milloy, PhD, Zach Walsh, PhD Published in Pain Medicine December 2020 Abstract Objective This article presents findings from a large prospective examination of Canadian medical cannabis patients, with a focus on the impacts of cannabis on prescription opioid use and quality of life over a…
Authors Carolina Chaves, MD, Paulo Cesar T Bittencourt, MD, MSc, Andreia Pelegrini, PhD Published in Pain Medicine October 2020 Abstract Objective To determine the benefit of a tetrahydrocannabinol (THC)-rich cannabis oil on symptoms and quality of life of fibromyalgia patients. Methods A double-blind, randomized, placebo-controlled clinical trial was conducted for eight weeks to determine the…
A study from Complementary Therapies in Medicine in 2020 examines patterns of cannabis use and its associated relief among migraineurs.
Authors: Emily M.Webster, Ghanshyam S.Yadav, Stefan Gysler, Blair McNamara, Jonathan Black, Joan Tymon-Rosario, Burak Zeybek, Chanhee Han, Christopher K. Arkfeld, Vaagn Andikyan, Gulden Menderes, Gloria Huang, Masoud Azodi, Dan-Arin Silasi, Alessandro D.Santin,Peter E.Schwartz, Elena S.Ratner, Gary Altwerger Published in Gynecologic Oncology Reports November 2020 Abstract Research within a gynecologic oncology population has lagged behind…
Authors: Kevin H Yang, Christopher N Kaufmann, Reva Nafsu, Ella T Lifset, Khai Nguyen, Michelle Sexton, Benjamin H Han, Arum Kim, Alison A Moore Published in Journal of the American Geriatrics Society October 2020 Abstract Background/objectives: Use of cannabis is increasing in a variety of populations in the United States; however, few investigations about how…
This study indicates that cancer survivors may indeed consume cannabis for symptom relief, and not merely for recreational purposes. More research is needed to study the adequate role that cannabis may have for treating symptoms associated with cancer survivorship.
Authors: Susanna A. Curtis, Dana Lew, Jonathan Spodick, Jeanne E. Hendrickson, Caterina P. Minniti, John D. Roberts Published in Blood Advances August 2020 Abstract More than one-third of adults with sickle cell disease (SCD) report using cannabis-based products. Many states list SCD or pain as qualifying conditions for medical marijuana, but there are few data…
Author: Sarah S. Stitha, Jegason P.Diviant, Franco Brockelman, KeenanKeeling, BrandenHall, Storri Lucern, Jacob M.Vigil, Kathleen MacMillan MacMillan, Amanda Keddy, James Furlon Published in Science Direct July 2020 Abstract Objective: Few studies to date have measured the real-time effects of consumption of common and commercially available Cannabis products for the treatment of headache and migraine under naturalistic…
Current Neuropharmacology, 19 April 2020
—
BACKGROUND: People with spinal cord injuries (SCI) commonly experience pain and spasticity, but limitations of current treatments have generated interest in cannabis as a possible therapy. OBJECTIVES: We conducted this systematic review to: 1) examine usage patterns and reason…
Clinical and experimental rheumatology, January-February 2020
—
OBJECTIVES: To assess any clinical improvement attributable to the addition of medical cannabis treatment (MCT) to the stable (>3 months) standard analgesic treatment of fibromyalgia (FM) patients, the retention rate and any changes in the concomitant analgesic treatment over …
Gynecologic Oncology, 10 January 2020
—
Tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN) affect the human endocannabinoid system. Cannabinoids reduce chemotherapy induced nausea or vomiting (CINV) and neuropathic pain. Each state has its own regulations for medical and recreational cannabis use. Ef…
Current Pharmaceutical Biotechnology, December 2019
—
BACKGROUND: Peripheral neuropathy can significantly impact the quality of life for those who are affected, as therapies from the current treatment algorithm often fail to deliver adequate symptom relief. There has, however, been an increasing body of evidence for the use of ca…